genedrive plc

LSE GDR.L

genedrive plc Net Income Margin for the year ending June 30, 2024: -1,412.18%

genedrive plc Net Income Margin is -1,412.18% for the year ending June 30, 2024, a 84.92% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

genedrive plc Net Income Margin for the year ending June 30, 2023 was -9,363.64%, a 1.86% change year over year.
genedrive plc Net Income Margin for the year ending June 30, 2022 was -9,540.82%, a -9,385.59% change year over year.
genedrive plc Net Income Margin for the year ending June 30, 2021 was -100.58%, a 94.51% change year over year.
genedrive plc Net Income Margin for the year ending June 30, 2020 was -1,833.71%, a -1,091.21% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

LSE: GDR.L

genedrive plc

CEO	Dr. Gino Miele Ph.D.
IPO Date	April 4, 2007
Location	United Kingdom
Headquarters	The CTF Building
Employees	43
Sector	Healthcare
Industries Biotechnology Autonomous Driving

Description

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.

Key trends

Past 5 years